CN
CNXU
Conexeu Sciences Inc.
$15.27
+0.20%
$385.7M
No data for this timeframe.
Vol
Market Cap$385.7M
Cap SizeSmall Cap
Reddit Sentiment55° Neutral
SEC Reports1
Press Releases1
Recent Activity
Jun 8, 2026
other
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 F
Jun 3, 2026
Press
Conexeu Sciences Inc. (CNXU) announced it will ring the Nasdaq Closing Bell on June 10, 2026, to celebrate its recent pu
Impact 2/10
May 26, 2026
Insider
Wright Michael G. sold 400,000 shares
10%+ Owner @ $0.001000 ($400.00)
May 26, 2026
Insider
Wright Michael G. sold 400,000 shares
10%+ Owner @ $0.00 ($0.00)
May 22, 2026
Insider
Sharpe Jeffrey Nathan sold 500,000 shares
Director @ $0.001000 ($500.00)
May 15, 2026
SEC
Insider cluster at Conexeu Sciences shows a $338K open-market purchase by a 10% owner, offset by a trivial sale and a no
CLUSTER — Impact 4/10
Latest Reports
NEUTRAL
Press
2/10
Conexeu Sciences Inc. (CNXU) announced it will ring the Nasdaq Closing Bell on June 10, 2026, to celebrate its recent pu
Jun 3, 2026
NEUTRAL
CLUSTER
4/10
Insider cluster at Conexeu Sciences shows a $338K open-market purchase by a 10% owner, offset by a trivial sale and a no
May 15, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 26, 2026 | Wright Michael | M | $400.00 |
| May 26, 2026 | Wright Michael | M | $0.00 |
| May 22, 2026 | Sharpe Jeffrey | M | $500.00 |
| May 22, 2026 | Sharpe Jeffrey | M | $0.00 |
| May 14, 2026 | Lorenc Zbigniew | A | $0.00 |
Reddit Sentiment
55°
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 26, 2026 | Wright Michael G. | 10%+ Owner | M | 400,000 | $0.001000 | $400.00 |
| May 26, 2026 | Wright Michael G. | 10%+ Owner | M | 400,000 | $0.00 | $0.00 |
| May 22, 2026 | Sharpe Jeffrey Nathan | Director | M | 500,000 | $0.001000 | $500.00 |
| May 22, 2026 | Sharpe Jeffrey Nathan | Director | M | 500,000 | $0.00 | $0.00 |
| May 14, 2026 | Lorenc Zbigniew Paul | Director | A | 11,175 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
55°
Neutral
Bearish
Neutral
Bullish
7 mentions
2 bullish
1 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| May 26, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 22, 2026 | 3 | 43° Neutral | 0 | 1 | 3 |
| May 22, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 8, 2026
other
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510(k) premarket notification submission <pre>A
Jun 3, 2026
activist
Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026
<p>RENO, Nev., June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=QqnIVwBEbfKxT0jC6KF-vM-sI4qk9IMhPDm1fal3cJVDVQ4
May 27, 2026
other
UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary